To evaluate whether IGFBP7 regulates the proliferation and migration of GC cells through the JAK/STAT signalling pathway, we treated cells with ruxolitinib (10 μM), a specific inhibitor of JAK1/2. Here, JAK1 is linked to gastric cancer.